Answers are grounded in this paper and cite their sources.
Randomized trial shows tocilizumab improves outcomes in rheumatoid arthritis, suggesting a new treatment pathway.
Evidence has accumulated indicating that proinflammatory cytokines play critical roles in the pathogenesis of RA. Recent clinical studies demonstrate that blockade of IL-6 signaling with tocilizumab, a recombinant humanized anti-interleukin-6 receptor antibody, is a new therapeutic option for the treatment of patients with RA refractory to conventional DMARD therapy and anti-TNF-α therapy. This paper discusses possible mechanisms of action, reviews the results of clinical trials, and discusses the place of tocilizumab in RA treatment.
No takes yet. Share an insight, caveat, or question.
Ohsugi et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: